Vagus nerve stimulation for chronic major depressive disorder: 12-month outcomes in highly treatment-refractory patients

被引:31
|
作者
Christmas, David [1 ]
Steele, J. Douglas [2 ]
Tolomeo, Serenella [2 ,3 ]
Eljamel, M. Sam [4 ]
Matthews, Keith [2 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Adv Intervent Serv, NHS Tayside, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Dept Neurosci, Dundee DD1 9SY, Scotland
[3] Univ Milano Bicocca, Milan, Italy
[4] Univ Dundee, Ninewells Hosp & Med Sch, Dept Neurosurg, Dundee DD1 9SY, Scotland
关键词
Major depressive disorder; Chronic depression; Vagus nerve stimulation; TREATMENT-RESISTANT DEPRESSION; PLACEBO-RESPONSE; METAANALYSIS; REMISSION; EFFICACY; RECURRENCE; RECOVERY; RELAPSE; BIPOLAR; TRIALS;
D O I
10.1016/j.jad.2013.05.080
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: There are limited treatment options for patients with chronic, treatment-refractory major depression who do not respond to routinely-available treatments. Vagus Nerve Stimulation (VNS) may represent an alternative to ablative neurosurgery for a specific group of patients. Methods: 12-month response rates for 28 patients with chronic (2 years) major depression who had failed to respond to >= 4 adequate treatment trials in the D03 European open clinical trial of VNS were described along with response rates for 13 consecutive patients who underwent VNS within the neurosurgical treatment programme in Dundee. Results: In the D03 cohort (N=28), the response rate at 12 months (defined as a 50% reduction in symptom score) was 35.7%. In the Dundee VNS case series (N=13), the equivalent response rate was 30.8%. Limitations: These data are from unblinded and open studies, and there is no control group. Other factors may have contributed to some of the improvement seen, although this is unlikely in very chronic populations. Outcomes are not reported beyond 12 months. Conclusion: Response rates at 12 months for patients with chronic and highly-refractory major depression are broadly consistent with previously published results in more heterogeneous and less refractory clinical trial populations. In highly treatment-resistant patients, the rate of response with VNS at 12 m is at least twice that anticipated with 'treatment-as-usual'. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:1221 / 1225
页数:5
相关论文
共 50 条
  • [1] Brain blood-flow change with acute vagus nerve stimulation in treatment-refractory major depressive disorder
    Conway, Charles R.
    Sheline, Yvette I.
    Chibnall, John T.
    Bucholz, Richard D.
    Price, Joseph L.
    Gangwani, Sunil
    Mintun, Mark A.
    [J]. BRAIN STIMULATION, 2012, 5 (02) : 163 - 171
  • [2] Neuromodulation for treatment-refractory major depressive disorder
    Lipsman, Nir
    Sankar, Tejas
    Downar, Jonathan
    Kennedy, Sidney H.
    Lozano, Andres M.
    Giacobbe, Peter
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2014, 186 (01) : 33 - 39
  • [3] A 12-month pilot study outcomes of vagus nerve stimulation in Crohn's disease
    Sinniger, Valerie
    Pellissier, Sonia
    Fauvelle, Florence
    Trocm, Candice
    Hoffmann, Dominique
    Vercueil, Laurent
    Cracowski, Jean-Luc
    David, Olivier
    Bonaz, Bruno
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 32 (10):
  • [4] Time Perception in Patients with Major Depressive Disorder during Vagus Nerve Stimulation
    Biermann, T.
    Kreil, S.
    Groemer, T. W.
    Maihoefner, C.
    Richter-Schmiedinger, T.
    Kornhuber, J.
    Sperling, W.
    [J]. PHARMACOPSYCHIATRY, 2011, 44 (05) : 179 - 182
  • [5] A distinct biomarker of continuous transcutaneous vagus nerve stimulation treatment in major depressive disorder
    Tu, Yiheng
    Fang, Jiliang
    Cao, Jin
    Wang, Zengjian
    Park, Joel
    Jorgenson, Kristen
    Lang, Courtney
    Liu, Jun
    Zhang, Guolei
    Zhao, Yanping
    Zhu, Bing
    Rong, Peijing
    Kong, Jian
    [J]. BRAIN STIMULATION, 2018, 11 (03) : 501 - 508
  • [6] Risperidone for treatment-refractory major depressive disorder - A Randomized trial
    Mahmoud, Ramy A.
    Pandina, Gahan J.
    Turkoz, Ibrahim
    Kosik-Gonzalez, Colette
    Canuso, Carla M.
    Kujawa, Mary J.
    Gharabawi-Garibaldi, Georges M.
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 147 (09) : 593 - 602
  • [7] Sleep disturbances and mood outcomes in patients with treatment-refractory major depressive disorder (MDD) receiving transcranial magnetic stimulation (TMS): a retrospective study
    Chopra, A.
    [J]. EUROPEAN PSYCHIATRY, 2020, 63 : S258 - S258
  • [8] P300 is enhanced in responders to vagus nerve stimulation for treatment of major depressive disorder
    Neuhaus, AH
    Luborzeswki, A
    Rentzsch, J
    Brakemeier, EL
    Gallinat, J
    Bajbouj, M
    [J]. BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 80S - 81S
  • [9] P300 is enhanced in responders to vagus nerve stimulation for treatment of major depressive disorder
    Neuhaus, A. H.
    Luborzewski, A.
    Rentzsch, J.
    Brakemeier, E. L.
    Opgen-Rhein, C.
    Gallinat, J.
    Bajbouj, M.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2007, 100 (1-3) : 123 - 128
  • [10] Metabolic features of treatment-refractory major depressive disorder with suicidal ideation
    Pan, Lisa A.
    Naviaux, Jane C.
    Wang, Lin
    Li, Kefeng
    Monk, Jonathan M.
    Lingampelly, Sai Sachin
    Segreti, Anna Maria
    Bloom, Kaitlyn
    Vockley, Jerry
    Tarnopolsky, Mark A.
    Finegold, David N.
    Peters, David G.
    Naviaux, Robert K.
    [J]. TRANSLATIONAL PSYCHIATRY, 2023, 13 (01)